ClinicalTrials.gg

Peripheral Arterial Disease clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,377 studies for Peripheral Arterial Disease across more than 10 countries. 275 are recruiting or about to start. 961 of them are mainly about Peripheral Arterial Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Chronic Limb-Threatening Ischemia: 1,697 studies, 330 open.

ClinicalTrials.gov finds 2,358 studies for Peripheral Arterial Disease. How that becomes 1,377 here

This page counts the studies the registry files under Peripheral Arterial Disease, and those it files under no condition that list Peripheral Arterial Diseasethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 2,358Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −316Filed under a narrower condition, counted on its own pageChronic Limb-Threatening Ischemia 219 · Intermittent Claudication 97
  3. −7List Peripheral Arterial Disease as a condition, but the registry did not file them under itMost often written as “PAD - Peripheral Arterial Disease” (4), “Symptomatic Peripheral Artery Disease (Symptomatic PAD)” (1), and “Occlusive Peripheral Arterial Disease” (1). The registry filed them under other conditions only, most often Coronary Artery Disease (1) and Peripheral Vascular Diseases (1).
  4. −658Match it another way61 name it in the title, 1 in a keyword, and 596 by a synonym or other text the search reads.
  5. 1,377The count on this page15 of them list Peripheral Arterial Disease in their own words; the registry filed them under no condition.

Status

Completed
718
Recruiting
193
Status unknown
188
Terminated
84
Not yet recruiting
71
Active, not recruiting
58

Phase

Phase 2
123
Phase 3
88
Phase 4
86
Phase 1
79
Early Phase 1
16

Where

United States
479
Germany
173
France
120
Belgium
85
United Kingdom
82
China
80

Who develops what

Add Peripheral Arterial Disease to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 8 companies, 4 with this as their studies’ main aim; 2 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Cook Group, Eli Lilly and Truway Health here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
RivaroxabanRecent, limited
Evidence
  • NCT07318610 · Regeneron Pharmaceuticals · Phase 3 · live · background · “Rivaroxaban” · registered Jan 2026
Bayer58% of its industry studiesUS: off-patent, 16 generics marketedEU: off-patent, 3 generics authorized11 study
AspirinRecent, limitedPhase 4 trial recorded
Evidence
  • NCT05730621 · Yuhan Corporation · Phase 4 · comparator · “Aspirin” · registered Jan 2023
  • NCT02227368 · AstraZeneca · Phase 2 · comparator · “Comparator” · registered Aug 2014
  • NCT01802775 · Daiichi Sankyo · Phase 2 · background · “Aspirin” · registered Feb 2013
Bayer25% of its industry studies11 study
ClopidogrelEarlier only
Evidence
  • NCT02121288 · AstraZeneca · Phase 4 · comparator · “clopidogrel” · registered Apr 2014
  • NCT01802775 · Daiichi Sankyo · Phase 2 · comparator · “Clopidogrel” · registered Feb 2013
  • NCT01732822 · AstraZeneca · Phase 3 · comparator · “Clopidogrel” · registered Nov 2012
Sanofi35% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 11 generics authorized00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
SirolimusApproved: US · EU 2001☆ Track1 live phase-3 study: NCT07359807concept medical inc
orforglipron☆ Track1 live phase-3 study: NCT07223593Eli Lilly and Company

The 2 in phase 3 with the nearest primary completion, of 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Mar 2027 est.Etribnabdione 25 mg BID · VivaCell Biotechnology España · Phase 2 main aimNCT06774040 Evaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease — primary endpoint: Incidence and severity of Treatment Emergent Adverse Events (TEAEs) · 30 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Peripheral Arterial Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here P2Y12 inhibitors 3 open · Factor Xa inhibitors 3 open · Antimitotic agents 3 open · mTOR inhibitors 2 open · GLP-1 receptor agonists 1 open

Coming up

89studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger. 13 (7%) take children under 18. 0 (0%) are for women only and 3 (2%) for men only; 19 (10%) take healthy volunteers.

Recruiting studies that take each age, of 193
AgeWomenMen
1013 (7%)13 (7%)
18143 (74%)144 (75%)
30159 (82%)161 (83%)
40173 (90%)175 (91%)
50187 (97%)189 (98%)
65189 (98%)192 (99%)
75186 (96%)189 (98%)
85165 (85%)167 (87%)

Across all 1,377 studies, recruiting or not: 6% stop at 75 or younger and 2% at 65; 5% take children; <1% are for women only and 1% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Peripheral Arterial Disease studies take

Of 28 phase 4 interventional studies under Peripheral Arterial Disease, half reached primary completion within 35 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 127 mo9–41 · 26 studies——
Phase 248 mo22–61 · 27 studies——
Phase 351 mo37–58 · 26 studies——
Phase 435 mo18–56 · 28 studies——
Interventional, no phase31 mo17–55 · 386 studies28 mo14–45 · 125 studies33 mo17–64 · 261 studies
Observational36 mo22–73 · 196 studies31 mo17–39 · 58 studies40 mo24–116 · 138 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting1

Studies

Recruiting first, then most recently updated. Showing 50 of 1,377. Browse all 1,377 → or search them.